8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2022)

Filed July 20, 2022For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on July 20, 2022, to announce its second quarter 2022 financial results. The filing primarily furnished a press release detailing these results. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, which exclude items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, and certain litigation and tax items. The company asserts that these non-GAAP measures provide greater visibility into ongoing business performance and are used internally for performance assessment.

Key Highlights

  • 1Abbott Laboratories reported its Q2 2022 financial results on July 20, 2022.
  • 2The results were presented via a press release furnished as an exhibit to the 8-K filing.
  • 3The company employs non-GAAP financial measures to report its performance.
  • 4Non-GAAP measures exclude items like acquisition costs, restructuring expenses, voluntary recall costs, and certain litigation/tax adjustments.
  • 5Abbott's management believes these non-GAAP measures offer a clearer view of ongoing operational performance.
  • 6Investors are advised to consider non-GAAP measures alongside GAAP measures.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the second quarter of 2022, as detailed in an accompanying press release.

Non-GAAP financial measures are financial metrics that exclude certain items from standard GAAP (Generally Accepted Accounting Principles) reporting. Abbott uses them to provide what they believe is a clearer view of their ongoing business performance by removing the impact of unusual or unpredictable items like acquisition costs, restructuring expenses, and voluntary recall costs.

While the 8-K itself does not provide specific financial figures, it states that the press release (Exhibit 99.1) contains the Q2 2022 results and details the adjustments made for non-GAAP measures, which include impacts from a voluntary recall.

The detailed Q2 2022 financial results are available in the press release issued by Abbott Laboratories on July 20, 2022, which is furnished as Exhibit 99.1 to this 8-K filing.